EXoPERT EMERALD Clinical Study

A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)

NCT06829199 ·Status: WITHDRAWN ·Phase: PHASE2

Utilizing Multiomic Advanced Diagnostics to Identify CDK 4/6 Inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients With ER+/HER2- Metastatic Breast Cancer

NCT03195192 ·Status: COMPLETED ·Phase: NA

Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer

NCT03523572 ·Status: COMPLETED ·Phase: PHASE1

Early On-treatment Transcriptional Profiling as Predictor of Response in Early-stage HER2-positive Breast Cancer

NCT05912062 ·Status: UNKNOWN

A Phase 1 Study of HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer

NCT04993430 ·Status: UNKNOWN ·Phase: PHASE1

Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies

NCT07309770 ·Status: RECRUITING ·Phase: PHASE2

Clinical Study of SHR-A1811 With or Without Letrozole in Neoadjuvant Therapy for Early-Stage HR-Positive, HER2-Low Breast Cancer

NCT07305246 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02

NCT05205200 ·Status: RECRUITING ·Phase: PHASE2

BMS-599626 in Patients With Advanced Solid Malignancies

NCT00095537 ·Status: COMPLETED ·Phase: PHASE1

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

NCT05306340 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study

NCT07307287 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

NCT06293898 ·Status: RECRUITING ·Phase: PHASE1

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

NCT06827236 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC

NCT02593175 ·Status: COMPLETED ·Phase: PHASE2

Camrelizumab in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-negative Breast Cancer

NCT07107217 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype

NCT05954442 ·Status: RECRUITING ·Phase: PHASE3

Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane

NCT02109913 ·Status: UNKNOWN ·Phase: NA

IMAGE Study: Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins

NCT01939847 ·Status: COMPLETED ·Phase: NA

Biomarkers for Clinical Classification and Outcomes of Immune Checkpoint Inhibitor-Related-Related Myocarditis in Lung Cancer

NCT06818149 ·Status: RECRUITING

Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer

NCT01582191 ·Status: COMPLETED ·Phase: PHASE1

Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer

NCT03566485 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Combination Study of SV-BR-1-GM With Retifanlimab

NCT03328026 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

NCT03650894 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

RC48 for Neoadjuvant Chemotherapy of HER2 Positive Breast Cancer

NCT05134519 ·Status: UNKNOWN ·Phase: PHASE2

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

NCT07159217 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2